A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.
Scientists used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial.
Personalized melanoma vaccines can be used to galvanize a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial.
Study examines vaccine therapy in prostate cancer with rising prostate-specific antigen (PSA) levelsJanuary 23, 2015
A vaccine therapy designed to boost the body's immune response may join available early treatment options for prostate cancer.
A breast cancer vaccine is safe in patients with metastatic breast cancer, as indicated by the results of an early clinical trial.
A DNA vaccine targeting the breast cancer-associated antigen mammaglobin-A was proven safe and found to effectively elicit immune responses in women with metastatic breast cancer, according to a new study.
The possibilities for personalized vaccines in all types of cancer were explored at the European Society for Medical Oncology Symposium on Immuno-Oncology 2014.
An experimental breast cancer vaccine boosts immune response and appears to slow spread in those with advanced disease.
Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.
Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.
In a new study, researchers examined the largest collection of tumor samples to date to predict patient-specific tumor mutations that may activate the patient's immune system, paving the way for more successful, personalized cancer immunotherapy.
A novel DNA vaccine is being employed to kill cancer, not by attacking tumor cells, but by targeting the blood vessels that keep them alive.
Early progress has been made in developing a treatment that might one day help the immune system defend itself against cancer, but research is still in preliminary stages.
A protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates immune functions was found to prolong survival in animal models for ovarian cancer and mesothelioma.
Women vaccinated with one dose of a HPV vaccine had antibodies against the viruses that remained stable in their blood for 4 years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses against new HPV infections, and ultimately cervical cancer.
Therapeutic vaccines for mucosal cancers may work best when administered directly at the site of those tumors rather than elsewhere.
The traditional view is that recurrent tumors are resistant to therapy because they acquired additional genetic mutations that make them more aggressive and impervious to drugs. However, these research findings alter that view.
A therapeutic vaccine for women who are already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small, phase 1 study.
Daclizumab, which prevents organ rejection after renal transplant, improved survival in persons with breast cancer receiving a therapeutic vaccine.
A vaccine significantly increased survival in mice with breast cancer when given with the hormonal therapy letrozole, but not with tamoxifen.
Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.
Many women with early breast cancer experienced a sustained immune response after immunization with a vaccine that fights HER2, and this may reduce their risk for more invasive cancer.
A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
A quadrivalent human papillomavirus (HPV) vaccine to prevent anal cancer was shown to be safe and effective in a trial of healthy men who have sex with men.
Recent study results suggest that a targeted immunotherapy based on a poxvirus may make chemotherapy for advanced non-small cell lung cancer more effective and slow disease progression.
Two sets of researchers identified a potential link between a microorganism and colon cancer after finding an abnormally large number of Fusobacterium cells in colorectal tumor samples.
The Cervarix vaccine for HPV may work with just one or two doses, rather than the standard three, according to an analysis of data from an National Cancer Institute (NCI)-sponsored trial.
In persons with stage III melanoma, frailty—not age—was associated with decreased disease-free survival and distant disease-free survival, and with more surgical complications.
Following the introduction of a human papillomavirus vaccination program, high-grade cervical abnormalities fell by nearly half in girls aged 17 years and younger in Victoria, Australia.
Smoking rates among US adults and youths have stalled over the past several years, but the increase in obesity appears to have slowed in the past decade.
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- 3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma
- Lung Cancer Navigator App Aims to Help Patients Understand Disease
- Racial Disparities Persist in Myeloma Treatment Use
- Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Melanoma Incidence Still on the Rise in Parts of the United States
- Frailty Classifications Associated With Prognosis Among Older Patients
- Beach Umbrella Not Enough for Protection from UV Rays
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC
- MABp1 Improves Symptoms vs Placebo in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|